CHICAGO – Improved radiotherapy techniques have made it possible for men to achieve reductions in PSA to below detectable levels following radiation treatment for prostate cancer, according to new ...
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.
SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products ...
Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the ...
Among men with PSA persistence after radical prostatectomy, a higher preoperative PSA surprisingly was linked to lower mortality. Men with PSA persistence and preoperative PSA >20 ng/mL had 31% lower ...
Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer. The drug combination of Lynparza (olaparib), Zytiga ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results